Register

Register for the eventRegister yourself and a team online now

Download a Brochure

Download the brochureDownload the Cool Chain 2009 Brochure

Join Now!

linkedin
Join our Linkedin group

Newsletter Sign-Up

Become a Pharma IQ member to receive our newsletter!

Poll

Which industry do you think has the strictest, challenging technical hurdles in maintaining temperatures?

Food
Biotech
Vaccines
Medical Device
Pharmaceuticals

Testimonials

Very valuable: great platform to exchange information and thoughts to vendors and business colleagues.
John van den Ender, Amgen Europe BV

January 27 - 29, 2009 • Sheraton Brussels Airport Hotel and Conference Centre, Brussels, Belgium



Conference Day Two: Thursday, 29th January, 2009

8.00 Morning Coffee

8.45 Chair’s Opening Remarks

Global Markets: International Cool Chains

8.50 Keynote Session: WCO Initiatives To Improve Security And Trade Facilitation In Today’s Global Pharmaceutical Market

  • Explaining the revised Kyoto convention and what key pharmaceutical markets such as India and China have agreed to
  • Developing unified and transparent customs procedures for industry to have one point of contact at the WCO, who then coordinates with FDA
  • SAFE Framework – Establishing a set of standards to provide supply chain security and facilitation at a global level to promote certainty and predictability
  • Promoting customs reform and modernisation IPR enforcement in new pharmaceutical markets

Michael Schmitz
Compliance and Facilitation Policy
World Customs Organisation

9.30 Assessing Airlines For Trusted Handling Of Pharmaceuticals Internationally And Implementing Effective Temperature Controlled Processes

  • Key challenges and examples of how temperature deviations still occur on airlines
  • Getting a grip with 0-25°C ambient temperatures on airlines: Describing the ideal solution
  • Gaining more insight into how airlines in international hubs such as Dubai handle and treat our products
  • Discussing label requirements for temperature sensitive medicinal freight
  • Understanding the difference in opinions between airport authorities and airlines with regards to ‘speciality products’ and how they should be handled

Ingo Ocklenburg
Global Sourcing Manager, Distribution Logistics
Bayer Healthcare

10.10 Cold Chain Packaging Carbon Footprint: Commercial Strategies For Reduction

  • Dispelling environmental myths and clarifying terms
  • Life Cycle analysis methodology and tools for cold chain packaging
  • Evaluating biodegradable packaging options for cold chain packaging
  • Application of the 4R’s to temperature control packaging
  • Sustainable supply chain strategies
  • Comparing approaches of different companies: what actions are being taken now?

David Walsh
CEO
DGP Group

10.50 Networking Break

11.20 Systems Applied To Ensure The Traceability Of Products All The Way To The Patient

  • Challenges in achieving true visibility of temperature controlled products
  • How to gain transparency and control of the supply chain through new technologies
  • Localised country solutions featuring Germany with RFID and the UK 's unique satellite tracking system

Jason Johnson
European Key Account Manager
Movianto Group

11.35 Best Practice Transportation Of Temperature-Sensitive Pharmaceuticals

Quality and consistency in transportation and temperature control, is significantly enhanced through the effective use of end-to-end custodial control, enroute monitoring and a capability for timely and effective contingency intervention. Effective pre shipment planning, including a mutual discussion of solution options between carrier and shipper, can significantly enhance quality and economy for pharmaceutical shippers.

  • Pre-assessment and shipment planning
  • En-route monitoring
  • Contingency planning
  • Evaluation of carriers' quality systems
  • Communication: Establishing an effective Transportation Quality Agreement
Tom Bolger
Logistics Specialist
Genzyme
Jeff Sitzlar
Manager, Business Development
FedEx Custom Critical

Panel Discussion:

12.15 Sea Transport Of Pharmaceutical Products: Exploring The Options And Defining Ways To Work Together

  • Examining current reefers on the market that afford cost-effective, low risk options for transporting pharmaceutical products
  • Discussing risks of sea transport: longer routes, port authorities and various other handlers
  • Defining how to overcome these key concerns in maintaining temperatures long-term via sea
  • Comparing efficiency of sea transport
  • Lessons learned in first shipments via sea

Panelists:

Henry Ames
Strategic Marketing Director
Sensitech
Jens Lamberth
Global Sourcing Manager
AstraZeneca
Phil Skelton
Senior Transportation Risk Manager
ACE European Group

To join as a panelist, contact courtney.becker@iqpc.co.uk

13.00 Networking Lunch

Track A
QA and Validation

Track B
Blue Sky Room: Cool Chain Process Improvements

14.00 Developing And Qualifying New Routes And New Packaging For Larger Volumes Of Biologic Product

  • Understanding the cost drivers
  • How to predict stability of biologic products
  • Evaluating frozen transportation options
  • Comparison with vaccine temperature management
  • Meeting regulatory expectations

Tom Bolger
Logistics Specialist
Genzyme

14.40 Fine Arts Case Study: Learning From An Industry Where 0% Risk Is The Standard

  • Challenges of fine arts transport temperature control +20°C
  • Risk awareness and comparing approaches on risk handling
  • Communication along the transport chain
  • Evaluating the impact of shock absorption
  • Relating temperature control challenges between pharmaceuticals and fine arts
  • Lessons for temperature controlled pharmaceuticals
Hans-Ewald Schneider
President
Hasenkamp Internationale Transporte GmbH
Joachim Kuhn
Physicist, CEO and Co-Founder
va-Q-tec AG

15.20 Networking Break

15.50 Ensuring An Effective Cool Chain In The Last Mile

  • Assessing requirements including validation master plan, routes, timelines to ensure an effective cold chain
  • Qualifying shipping systems and assessing suitability
  • Adopting a bracketing approach to cold chain validation studies

Nigel Bleakley
Validation Engineer
UCB Celltech

16.30 Panel Discussion: Risk Assessment Of The Cool Chain

  • When And Where Does A Risk Assessment End?
  • What Exactly Do The Airlines Control?
  • Identifying What Risks Exists At Custom Points And Routes
  • There Is QA. There Is Logistics. But Who’s Responsible For Quality Logistics?

All speakers and participants of this afternoon are invited to join this discussion

17.10 Chair’s Closing Remarks

14.00 Amgen Continuous Process Improvements In The Cold Chain Case Study: Planning For Long-Term Compliance And Efficient Operations

  • Drivers for initiating a Cold Chain Excellence Programme
  • Matching transport method with the product and regulatory requirements
  • Measuring transport lanes in order to increase performance and optimise costs
  • What tools and methods can be implemented to improve control over our third parties (carriers, local stock points)

Martine Nolan
Senior Manager, Quality Assurance
Amgen

14.40 Abbott Cold Chain Kiazen Case Study: Improving Storage, Distribution And Transportation Operations

  • Drivers for process improvements in our cold chain
  • Achieving standardised work processes
  • Areas of cost reduction
  • Environmentally conscious continuous process improvements

Gert-Jan Van Diest
Cold Chain Manager, Logistics
Abbott

15.20 Networking Break

15.50 Implementing A New Warehouse Management System As Part Of A Long-Term Strategic Roadmap For Temperature Control

  • Drivers for a new WMS system
  • Meeting increasing regulatory and customer requirements
  • Examples of Beta projects tracking temperature control products throughout the supply chain
  • Automating key processes from inbound goods arrival and processing through inventory storage to fulfilling outbound shipping orders
  • Developing and using stability tracking data for continuous process improvements

Pier Pollini
Director of Supply Chain Execution
Baxter Healthcare

Panel Discussion

16.30 End To End Cool Chain Transportation Processes And The Role Of Outsourcing

  • New trends in biopharmaceuticals
  • How to make processes more solid to minimise human error
  • Working with partners that understand what Good Cold Chain Management practices are
  • The value of end to end service providers
  • Management buy-in – Who is responsible for cost-effective cool chains and outsourcing decisions?

All Blue Sky Room speakers and participants invited to join the discussion

17.10 Chair’s Closing Remarks